已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Effect of continuing osimertinib with chemotherapy in the post-progression setting on progression-free survival among patients with metastatic epidermal growth factor receptor (EGFR) positive non-small cell lung cancer.

奥西默替尼 医学 肿瘤科 内科学 队列 无进展生存期 肺癌 危险系数 化疗 比例危险模型 回顾性队列研究 表皮生长因子受体 癌症 置信区间 埃罗替尼
作者
Tejas Patil,David Chun Cheong Tsui,Andrew Nicklawsky,Erin L. Schenk,W. Thomas Purcell,Paul A. Bunn,Jose M. Pacheco,D. Ross Camidge
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:39 (15_suppl): 9124-9124 被引量:3
标识
DOI:10.1200/jco.2021.39.15_suppl.9124
摘要

9124 Background: Continuing a 1st generation EGFR TKI with chemotherapy upon TKI progression was not shown to be beneficial in the IMPRESS trial. However, the validity of this approach with osimertinib remains under explored. We attempted to characterize the efficacy of continuing osimertinib with chemotherapy in the post-progression setting. Methods: A single-center retrospective review of patients with metastatic EGFR mutant NSCLC who had progressed on osimertinib was performed. Clinical characteristics and treatment outcomes were noted. Progression free survival (PFS), duration of treatment (DOT), overall survival (OS) and rates of intracranial progression were captured. ANOVA or a Fisher exact test were used to identify associations between cohort characteristics and treatment outcomes. Differences in PFS, DOT and OS were assessed using a log-rank test. A Cox proportional hazard model was used to adjust for potential confounders. Results: 73 patients with EGFR mutant NSCLC with post-osimertinib treatment outcomes were identified. Cohort characteristics are summarized in Table. Median duration of follow up was 41 months. Upon progression, osimertinib was discontinued in 34 patients (Cohort A) and continued with next line of therapy in 39 patients (Cohort B). Survival analyses were adjusted for prior lines of therapy, use of platinum doublet chemotherapy, and use of immune checkpoint inhibitors in the post-progression setting. After adjusting for covariates, continuing osimertinib post-progression was associated with an improved PFS (7 vs 4 months; HR 0.58; 95% CI 0.34 – 1.00; p = 0.003) and DOT (7 vs 4 months; HR 0.52; 95% CI 0.31 – 0.87; p = 0.006). There was no difference in OS between Group A and B (52 vs 41 months; HR 0.73; 95% CI 0.43 – 1.24; p = 0.234). Rates of intracranial progression were similar between Group A and B (28% vs 23%; p = 0.649). Conclusions: After adjusting for covariates, continuing osimertinib with chemotherapy in the post-progression setting was associated with a significant difference in PFS and DOT, but with no differences in OS. Continuing osimertinib does not appear to influence the rate of subsequent intracranial progression. Prospective studies are needed to identify the optimal practice pattern.[Table: see text]

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
哈哈哈哈完成签到 ,获得积分10
刚刚
星辰大海应助冷灰天花板采纳,获得10
5秒前
6秒前
李爱国应助Zhang采纳,获得10
7秒前
7秒前
11秒前
别找了睡觉吧完成签到 ,获得积分10
13秒前
13秒前
jacs111完成签到,获得积分10
13秒前
kokocrl完成签到,获得积分10
14秒前
恋雅颖月完成签到 ,获得积分10
14秒前
zs完成签到 ,获得积分10
15秒前
gszy1975完成签到,获得积分10
17秒前
18秒前
lengyan发布了新的文献求助10
19秒前
小禾一定行完成签到 ,获得积分10
20秒前
21秒前
占稚晴完成签到 ,获得积分10
25秒前
26秒前
28秒前
星辰大海应助zlovej采纳,获得10
28秒前
吾日三省吾身完成签到 ,获得积分10
29秒前
小马甲应助lengyan采纳,获得10
29秒前
烟花应助lengyan采纳,获得10
29秒前
知足的憨人丫丫完成签到,获得积分10
30秒前
ymygdz发布了新的文献求助10
31秒前
Jasper应助坦率迎海zbj采纳,获得10
32秒前
聂难敌发布了新的文献求助10
34秒前
了晨完成签到 ,获得积分10
36秒前
得了道的小神仙完成签到,获得积分10
39秒前
该房地产个人的完成签到,获得积分10
39秒前
39秒前
英俊的铭应助科研通管家采纳,获得10
41秒前
41秒前
41秒前
852应助科研通管家采纳,获得10
41秒前
Akim应助科研通管家采纳,获得10
41秒前
41秒前
知足的憨人*-*完成签到,获得积分10
43秒前
kkssrrrr完成签到 ,获得积分10
44秒前
高分求助中
Evolution 10000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Distribution Dependent Stochastic Differential Equations 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3158547
求助须知:如何正确求助?哪些是违规求助? 2809652
关于积分的说明 7883366
捐赠科研通 2468389
什么是DOI,文献DOI怎么找? 1314115
科研通“疑难数据库(出版商)”最低求助积分说明 630572
版权声明 601963